Brosmed Artimes™ Pro receives FDA Clearance for Treating Chronic Total Occlusions (CTO) in PTCA Intervention
Release time:
2021-05-24
Guangdong ,China [May 24 , 2021] – Brosmed Ltd. today announced that she has received a 510(k) clearance from the U.S. Food & Drug Administration for its Artimes™ Pro PTCA balloon catheter. Artimes™ Pro is a novel PTCA semi-compliant rapid-exchange balloon dilatation catheter manufactured with specific features to facilitate complex coronary interventions.
Guangdong ,China [May 24 , 2021] – Brosmed Ltd. today announced that she has received a 510(k) clearance from the U.S. Food & Drug Administration for its Artimes™ Pro PTCA balloon catheter.
Artimes™ Pro is a novel PTCA semi-compliant rapid-exchange balloon dilatation catheter manufactured with specific features to facilitate complex coronary interventions. Its soft and laser-welded distal tip with an entry profile of 0.016” for the 1.00 mm and 1.25 mm, favor the deep engagement in the tight lesions or the CTO micro channels with a smooth a-traumatic lesion entry. Moreover, a novel balloon material ensures a low wrapping profile. The distal shaft coating Slider™, a biocompatible, hydrophilic, lubricious coating of the distal balloon base up to the rapid-exchange port, is another feature that improves trackability of the device across long, tortuous, and calcified lesions.
The seamless single-tube transition to the hypotube improves pushability allowing for superior force transmission without any loss during navigation.
These characteristics make the device truly competitive, in terms of penetration power, crossing profile, and pushability, with the best available CTO balloons.
BrosMed Medical is constantly expanding the product portfolio in the field of coronary angioplasty. The Artimes™ ( K141025, 1.5-4.0 mm) balloon portfolio has been sold in United States since 2015 and distributed in more than 50 countries around the world. Artimes™ Pro is a significant new addition to the CTO toolbox for tackling complex lesions in the USA market.
About BrosMed Medical
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
Join with Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announced CE MDR Approval of New Generation Conger™ Plus Hydrophilic Guidewires
Designed for superior crossability and maneuverability in peripheral interventions, Conger Plus now offers 116 models with expanded sizes (OD 0.018'' to 0.038'') and lengths (up to 300cm).
2025-04-25
Meet BrosMed at ESC Congress 2024
BrosMed Medical is delighted to participate in the ESC Congress 2024 from August 30th to September 2nd in London, UK.
2024-08-15
BrosMed Medical Announces Scott J. Addonizio as Chief Operating Officer
2024 August 1st – BrosMed Medical is pleased to announce the appointment of Scott J. Addonizio as its Chief Operating Officer (COO), effective immediately. Mr. Scott J. Addonizio brings a wealth of experience and expertise to BrosMed, with a distinguished career spanning almost 30 years in the medical device industry. Prior to joining BrosMed, Mr. Addonizio served as SVP at Cordis and COO at MedAlliance Swiss Medical Technology.
2024-08-01
CTO&CHIP PCI – Insights from the clinical practice (Ⅱ)
July 30, 2024 @16:00-17:30 (Beijing Time) Join BrosMed Medical on Tuesday, July 30 for an enlightening discussion that unites cardiologists from Malaysia, China, India, Tunisia and Portugal, where clinical expertise harmoniously fuses with CTO&CHIP innovation. At this exclusive webinar, we’re orchestrating a confluence of valuable insights, drawing from the collective wisdom of seasoned interventional cardiologists.
2024-07-26
BrosMed Announced CE MDR Approval of New Generation PTA SC Balloon Dilatation Catheters
May 27, 2024- BrosMed announced that it receives European Medical Device Regulation (MDR) certification for the New Generation PTA SC Balloon Dilatation Catheters (Brand Name: Polux™ Pro 014, Minerva™ Pro 018 and Atropos™ Pro 035).
2024-05-27